Eric VIVIER and Bernard MALISSEN, team leaders at the Marseille-Luminy Immunology Center, are on the 2020 list of the most cited researchers in the world for the fourth time, as in previous editions 2016, 2017, 2018 and 2019.Published annually by the prestigious Clarivate Analytics Company, previously Thomson Reuters, this ranking recognizes authors of the most frequently cited publications in the scientific community.A recognition mark that rewards the value of their discoveries and the exceptional research influence in their scientific field.

See the list

Initial translational analysis, EXPLORE, showed overexpression of C5a/C5aR pathway in patients with severe COVID-19The primary objective of this investigator-sponsored trial, named FORCE, is to improve the proportion of COVID-19 patients with severe pneumonia who no longer need to be hospitalized, and to reduce the need for and duration of mechanical ventilation in patients with COVID-19 pneumonia complicated by acute respiratory distress syndrome (ARDS).

Through the translational data analysis in COVID-19 patients, we observed high levels of circulating C5a and over-activation of the C5a-dependent myeloid cell pathway, which is believed to contribute to inflammation in the lungs. Avdoralimab is a monoclonal antibody that blocks C5aR and has the potential to reduce the inflammatory response in the lungs, said Pr. Eric Vivier, PhD, Chief Scientific Officer at Innate Pharma and Professor at AP-HM (Marseille Public University Hospitals), Aix-Marseille University and Centre dImmunologie de Marseille-Luminy, CNRS, Inserm and AMU.More information

A Franco-German research team led by Prof. Michael Sieweke, from the Center for Regenerative Therapies TU Dresden (CRTD) and the Center of Immunology of Marseille Luminy (CNRS, INSERM, Aix-Marseille University), today uncovered a surprising property of blood stem cells: not only do they ensure the continuous renewal of blood cells and contribute to the immune response triggered by an infection, but they can also remember previous infectious encounters to drive a more rapid and more efficient immune response in the future. These findings should have a significant impact on future vaccination strategies and pave the way for new treatments of an underperforming or over-reacting immune system. The results of this research are published in Cell Stem Cell on March 12, 2020. More information

C/EBP-Dependent Epigenetic Memory Induces Trained Immunity in Hematopoietic Stem Cellsde Laval B., Maurizio J., Kandalla P K., Brisou G., Simonnet L., Huber C., Gimenez G., Matcovitch-Natan O., Reinhardt S., David E., Mildner A., Leutz A., Nadel B., Bordi C., Amit I., Sarrazin S.*,., Sieweke M H.*,. Cell Stem Cell, 2020 , pii: S1934-5909(20)30017-5, PMID: 32169166

See the original post:
Home | CIML